Sufentanil limits the myocardial infarct size by preservation of the phosphorylated connexin 43

International Immunopharmacology
Yun WuWei-Ping Fang

Abstract

Sufentanil, with a potent analgesia effect, has been wildly used in anesthesia and analgesia, especially for the cardiovascular surgeries. The aim of the study was to evaluate whether sufentanil provides cardioprotection and the effect of connexin 43 on the cardiac infarct size reduction. Sufentanil post-conditioning (bolus injection at 0.1, 0.3, 1, 3, 10 μg/kg) or ischemic post-conditioning (3 cycles of a 10s reperfusion alternating with a 10s ischemia) was induced in an intact rat heart model of ischemia-reperfusion injury. Both ischemic and sufentanil post-conditioning reduced the myocardial infarct size compared with control group. The infarct size limitation of sufentanil was dose-dependent, 1 μg/kg has the optimal effect and increasing dosage could not afford further cardioprotection. Connexin 43 underwent dephosphorylation in response to ischemia-reperfusion measured by Western blot at the anterior myocardium tissues of left ventricle while sufentanil preserved the phosphorylation of connexin 43. The results demonstrated that sufentanil limits myocardial infarct size which is similar with ischemic post-conditioning at the dosage of 1 μg/kg. Preservation of phosphorylation of connexin 43 plays an important role in the car...Continue Reading

References

Jun 1, 1991·Journal of Molecular and Cellular Cardiology·A F LauD S Crow
Dec 1, 1987·The Journal of Cell Biology·E C BeyerD A Goodenough
Aug 7, 1999·Circulation Research·M Ruiz-MeanaJ Soler-Soler
May 23, 2001·Archives of Biochemistry and Biophysics·P D Lampe, A F Lau
Jul 27, 2001·Cardiovascular Research·A A van VeenT Opthof
May 6, 2003·Circulation Research·Sandeep K JainJeffrey E Saffitz
Jul 16, 2003·American Journal of Physiology. Heart and Circulatory Physiology·Zhi-Qing ZhaoJakob Vinten-Johansen
Feb 14, 2004·Cardiovascular Research·H M PiperC Schäfer
Feb 14, 2004·Cardiovascular Research·David García-DoradoMarisol Ruiz-Meana
Apr 20, 2004·Cardiovascular Research·Rainer Schulz, Gerd Heusch
Apr 20, 2004·Cardiovascular Research·Nicholas J SeversTsutomu Matsushita
Jun 1, 2005·Biochimica Et Biophysica Acta·Gina E Sosinsky, Bruce J Nicholson
Jun 16, 2005·Biochimica Et Biophysica Acta·Joell L Solan, Paul D Lampe
Jan 31, 2006·Cardiovascular Research·Amanda J ZattaJakob Vinten-Johansen
Feb 14, 2006·Lancet·Derek M Yellon, Lionel H Opie
May 18, 2007·Progress in Biophysics and Molecular Biology·Alonso P Moreno, Alan F Lau
Sep 18, 2007·British Journal of Anaesthesia·C K YuM G Irwin
Dec 25, 2007·The Journal of Surgical Research·Zuolei ChenBingxi Zhang
Jan 10, 2008·Journal of Cellular and Molecular Medicine·C PennaP Pagliaro
Oct 7, 2008·American Journal of Physiology. Heart and Circulatory Physiology·Andreas TotzeckRainer Schulz
Mar 25, 2009·The Biochemical Journal·Joell L Solan, Paul D Lampe
Jul 11, 2009·Circulation Journal : Official Journal of the Japanese Circulation Society·Kaori Shintani-IshidaKen-ichi Yoshida
Aug 27, 2009·Circulation Journal : Official Journal of the Japanese Circulation Society·Tohru Minamino
Jun 1, 2010·Experimental Biology and Medicine·Sandrine LemoineJean-Luc Hanouz

❮ Previous
Next ❯

Citations

Oct 15, 2014·Journal of Cardiothoracic and Vascular Anesthesia·Youmei ZuoYuanyuan Cao
May 21, 2016·Medicinal Research Reviews·Leonid N MaslovJames M Downey
Feb 23, 2017·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·Q XuB Liu
Dec 19, 2014·British Journal of Pharmacology·John P HeadrickJason N Peart
Sep 22, 2017·Pharmacological Reviews·Luc LeybaertRainer Schulz
Jul 12, 2020·Clinical Hemorheology and Microcirculation·Xin-Yue ZhangRong-Hui Tu
Apr 10, 2020·Coronary Artery Disease·Wenjiang YanJingjing Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Related Papers

Circulation Journal : Official Journal of the Japanese Circulation Society
Tohru Minamino
Heart Failure Reviews
Rainer SchulzGerd Heusch
Progress in Biophysics and Molecular Biology
Antonio Rodriguez-SinovasDavid García-Dorado
© 2021 Meta ULC. All rights reserved